These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30862490)

  • 21. Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention.
    Wustrow I; Sarafoff N; Haller B; Rössner L; Sibbing D; Schüpke S; Ibrahim T; Anetsberger A; Schunkert H; Laugwitz KL; Kastrati A; Bernlochner I
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):1239-1246. PubMed ID: 30019824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
    Li J; Ju J; Chen Z; Liu J; Lu F; Gao R; Xu H
    Trials; 2018 Feb; 19(1):93. PubMed ID: 29415754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
    Hohnloser SH; Steg PG; Oldgren J; Nickenig G; Kiss RG; Ongen Z; Navarro Estrada JL; Oude Ophuis T; Lip GYH; Nordaby M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1553-1561. PubMed ID: 31439336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis.
    Wang Q; Yang K
    Medicine (Baltimore); 2021 Apr; 100(15):e25546. PubMed ID: 33847681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. A meta-analysis.
    Chen CF; Chen B; Zhu J; Xu YZ
    Herz; 2015 Dec; 40(8):1070-83. PubMed ID: 26135462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
    Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
    Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
    Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    Piccolo R; Feres F; Abizaid A; Gilard M; Morice MC; Hong MK; Kim HS; Colombo A; Bhatt DL; Palmerini T; Stone GW; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1621-1630. PubMed ID: 28838471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy.
    Sharma T; Rylance R; Karlsson S; Koul S; Venetsanos D; Omerovic E; Fröbert O; Persson J; James S; Erlinge D
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):6-13. PubMed ID: 31093662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should all stent patients have prolonged dual antiplatelet therapy?
    Kirtane AJ; King SB
    JACC Cardiovasc Interv; 2015 May; 8(6):873-875. PubMed ID: 25999115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.